ArticleNeurology and therapy2026
Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMyasthenia gravis (MG) is an autoimmune neurological disorder affecting the neuromuscular junction. Rapid clinical deterioration during a myasthenic crisis (MC) or severe exacerbation may be life-threatening due to respiratory or bulbar involvement. Plasma exchange (PLEX) and intravenous immunoglobulin (IVIg) are two rescue therapies that show comparable efficacy in this setting. However, the characteristics of patients who respond poorly to IVIg remain insufficiently described. The aim of this study was to identify predictive factors of non-response to IVIg administered during a first MC or exacerbation.
methodsThis was a single-centre retrospective cohort study carried out at a French referral centre for neuromuscular diseases between 2017 and 2023. Adult patients with generalised MG experiencing a first MC or exacerbation and treated for the first time with IVIg were included in the study. Data on clinical, laboratory, electrophysiological and therapeutic variables were collected. Treatment response was defined as the maximum gain in Garches clinical score following IVIg, adjusted for baseline score.
resultsA total of 93 were included in the study. The median age of the cohort was 68 (interquartile range [IQR] 49-76) years, and the median delay from diagnosis was 0.7 years. The median baseline Garches score was 66/100 (IQR 55-75) points, which improved to 85/100 (IQR 75-94) points after treatment. Bulbar involvement was significantly associated with a greater response to IVIg.
conclusionsIn this large and heterogeneous cohort, IVIg demonstrated consistent efficacy without identification of significant predictors of non-response. These findings support IVIg as a reliable and evidence-based first-line therapy for patients with MG experiencing exacerbation or MC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.